News | January 07, 2015

Six abstracts cover topics including patient-specific dose, applied pressure


January 7, 2015 — The value of volumetric breast imaging data to provide critical insight for optimal breast imaging quality and workflow was the focus of numerous abstracts accepted for presentation at the 100th Annual Meeting of the Radiology Society of North America (RSNA), November 30-December 5, 2014. 

According to Volpara Solutions, six abstracts highlight the use of quantitative breast imaging software tools to provide breast imaging and analytics data. Presented data types including volumetric density, patient-specific dose, applied pressure and other factors designed to maintain accuracy and consistent quality in breast screening using digital mammography and digital breast tomosynthesis.

In the scientific exhibit, “Can we use the manufacturer reported mammography dose to inform patients?” (BRS263), researchers from Elizabeth Wende Breast Center reviewed manufacturer-reported mean-glandular dose (MGD) for 30 women who had undergone sequential screening mammograms on a mix of three manufacturers’ systems. The manufacturer-reported MGD varied considerably sequential mammograms and between manufacturers, with changes ranging from -2.87 to +4.31 mGy.  Additionally, since the algorithms used by manufacturers vary, the estimations are not easily compared.

This is consistent with other research, which has demonstrated that mammography units routinely under- or overestimate dose because they do not include the patient’s specific volumetric breast density in the estimation. In another abstract examining patient dose in mammography, “System-wide monitoring of mammographic radiation dose for quality assurance”, researchers from Weinstein Imaging used VolparaAnalytics on more than 11,000 images to compare manufacturer-reported MGD to a patient-specific estimate. Automated stratification of the data by mammography unit suggested that one vendor underestimated MGD compared to the patient-specific dose calculations, despite similar breast density characteristics of the populations. The abstract concludes that for more accurate reporting of MGD, it is essential that a standardized method be used across all manufacturers’ systems.

"At Weinstein Imaging, we want to ensure our patients are safe and informed during screening. Part of that includes monitoring and recording patient dose. Volpara enables true comparison of dose across machines so that we can spot issues early and truly keep women safe and informed," said Marcela Böhm-Vélez, practicing radiologist and president of Weinstein Imaging.

Accurate breast density estimation is important for breast cancer risk assessment and guiding personalized breast screening recommendations. In the presentation, “Fully automated volumetric breast density estimation from digital breast tomosynthesis images: Multimodality comparison with digital mammography and breast MRI”, researchers from the University of Pennsylvania reviewed results of a study to evaluate the feasibility of automated volumetric breast density for breast tomosynthesis and compared the results to digital mammography and breast magnetic resonance imaging (MRI). The abstract concludes that volumetric breast density estimates from breast tomosynthesis data sets were highly correlated to density estimates from digital mammography and MRI, and hold the potential for more accurate density assessments and more accurate measures of breast cancer risk. 

In addition, the “Breast Imaging Breast Density & Risk Assessment” session included three presentations that featured VolparaDensity: ”Automated volumetric breast density and risk of cancer stratified by pathological attributes,” “Comparing breast density measurement techniques in screening digital mammography” and  “The diagnostic effect of digital breast tomosynthesis in relation to visually assessed and automated volumetric breast density.”  The role of volumetric density in adjunctive imaging for women with dense breasts was the topics of numerous presentations.

For more information: www.volparasolutions.com


Related Content

News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
News | Women's Health

Dec. 12. 2025 — A new study has found that an individualized approach to breast cancer screening that assesses patients’ ...

Time December 17, 2025
arrow
News | Breast Imaging

Dec. 16, 2025 — Hologic, Inc, a medical technology company dedicated to improving women’s health, recently announced new ...

Time December 16, 2025
arrow
News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
Subscribe Now